FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera
Portfolio Pulse from
The FDA has granted orphan-drug designation to Jaguar Health's drug, Crofelemer, for treating diarrhea in cholera. This comes amid a global cholera resurgence, highlighting the drug's potential importance.
December 17, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's Crofelemer has received FDA orphan-drug designation for treating diarrhea in cholera, potentially boosting the company's market position amid a global cholera resurgence.
The FDA's orphan-drug designation for Crofelemer is significant as it addresses a critical health issue, potentially increasing demand and market interest in Jaguar Health. The global cholera resurgence further underscores the drug's relevance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100